Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs
Jun Li(Sun Yat-sen University), Yongjun Guo(Tianjin Agricultural University), Junnan Feng(Zhengzhou University), Klaas Kok(University Medical Center Groningen), Sile Han(Zhengzhou University), Yuping Guan(Zhengzhou University), Hongle Li(Shanghai Jiao Tong University), Jiawen Zheng(Zhengzhou University), Shasha Li(Harvard University), Pengfei Ren(Zhengzhou University), Jie Ma(Renal Research Institute), Bing Wei(Guangdong Medical College), Ruijuan Ma(Jiangsu Academy of Agricultural Sciences), Cuiyun Zhang(Zhengzhou University), Siyu Wang(First Hospital of China Medical University), Anke van den Berg(University Medical Center Groningen)
Cited by 4
Related Papers
MEK inhibitors for the treatment of non-small cell lung cancer
|Journal of Hematology & Oncology|2021|300
SETD2: an epigenetic modifier with tumor suppressor functionality
|Oncotarget|2016|167